Centogene

For 2020, the company reported €128.4 million in revenues, including €89.3 million from COVID-19 testing, more than doubling its 2019 revenues of €48.8 million.

Diagnostics revenues were €32.5 million in Q3, up almost fivefold from €6.8 million last year, and included €27.4 million from commercial coronavirus testing.

The study, called TRAMmoniTTR, will longitudinally monitor the clinical status of both symptomatic and asymptomatic participants with variants in the TTR gene.

News items for the in vitro diagnostics industry for the week of Nov. 23, 2020.

Centogene will install Fujirebio's Lumipulse G1200 instruments in its laboratories to analyze samples it collects from travelers using its oropharyngeal swabs.

News items for the in vitro diagnostics industry for the week of Nov. 2, 2020.

The German diagnostics firm expects more than €80 million in 2020 revenues, driven by its recovering core business and its COVID-19 testing business.

Centogene will provide its oropharyngeal swabs and conduct RT-PCR testing, while U-Diagnostics will collect samples and report the results.

News items for the in vitro diagnostics industry for the week of Sept. 28, 2020.

The tests are designed to detect viral nucleic acid in various respiratory specimens including nasal swabs, nasal aspirate, and bronchoalveolar lavage.